Paragon Biosciences

Founded in 2020, Evozyne is a biotechnology company specializing in protein design using its data-driven evolution-based molecular engineering platform. Headquartered in Chicago, Illinois, the company focuses on therapeutic discovery and drug development to create novel proteins with advanced functionality.

Emalex Biosciences is a biotechnology startup focused on developing innovative treatments for central nervous system (CNS) disorders and rare neurological conditions. Founded in 2018 by Jeff Aronin, the company is advancing its lead candidate, Ecopipam, which has been explored as a potential therapy for various CNS disorders, including pediatric Tourette Syndrome and fluency disorders. Emalex aims to address the needs of patients with rare diseases that currently have limited or no treatment options, collaborating with patient advocacy organizations and medical researchers to facilitate the development of effective biopharmaceutical therapies.

Castle Creek Biosciences is a gene therapy company dedicated to developing personalized treatments for rare skin and connective tissue disorders with high unmet medical need. Its approach centers on patient-derived fibroblast cells to create localized cell and gene therapies tailored to each patient's biology, offering options where therapies are limited. The company is headquartered in Exton, Pennsylvania, and was founded in 2015.

Emalex Biosciences is a biotechnology startup focused on developing innovative treatments for central nervous system (CNS) disorders and rare neurological conditions. Founded in 2018 by Jeff Aronin, the company is advancing its lead candidate, Ecopipam, which has been explored as a potential therapy for various CNS disorders, including pediatric Tourette Syndrome and fluency disorders. Emalex aims to address the needs of patients with rare diseases that currently have limited or no treatment options, collaborating with patient advocacy organizations and medical researchers to facilitate the development of effective biopharmaceutical therapies.

Castle Creek Biosciences is a gene therapy company dedicated to developing personalized treatments for rare skin and connective tissue disorders with high unmet medical need. Its approach centers on patient-derived fibroblast cells to create localized cell and gene therapies tailored to each patient's biology, offering options where therapies are limited. The company is headquartered in Exton, Pennsylvania, and was founded in 2015.